Targeted biologic therapies have revolutionised treatment of immune-mediated
inflammatory diseases (IMIDs) due to their efficacy, speed of onset and tolerability. The …

The past three decades have witnessed remarkable advances in our ability to target specific
elements of the immune and inflammatory response, fuelled by advances in both …

Tumour necrosis factor (TNF) plays an important role in the pathogenesis of immune-
mediated inflammatory diseases (IMIDs). TNF inhibition results in down-regulation of …

Immune-mediated inflammatory disorders (IMIDs) are a group of diseases that involve an
immune response that is inappropriate or excessive, and is caused, signified, or …

Immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis, psoriatic
arthritis, psoriasis, axial spondyloarthropathies, Crohn's disease, ulcerative colitis and …

TNF-α is a potent inducer of the inflammatory response, a key regulator of innate immunity
and plays an important role in the regulation of Th1 immune responses against intracellular …

Introduction: TNF-α inhibitors have demonstrated efficacy both as monotherapy and in
combination with disease-modifying antirheumatic drugs (DMARDs) in the treatment of …

Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …

The term “immune-mediated inflammatory diseases (IMIDs)” refers to several inflammatory
pathologies of multifactorial etiology and involving either simultaneously or sequentially …

Abstract Treatment of inflammatory arthritides-including rheumatoid arthritis, ankylosing
spondylitis, and psoriatic arthritis-has seen much progress in recent years, partially due to …